250 related articles for article (PubMed ID: 26842686)
21. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE
Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152
[TBL] [Abstract][Full Text] [Related]
22. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis.
Thom H; Thompson JC; Scott DA; Halfpenny N; Sulham K; Corey GR
Curr Med Res Opin; 2015 Aug; 31(8):1539-51. PubMed ID: 26038985
[TBL] [Abstract][Full Text] [Related]
24. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
Bouza E; Burillo A
Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
[TBL] [Abstract][Full Text] [Related]
25. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Jorgenson MR; DePestel DD; Carver PL
Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
[TBL] [Abstract][Full Text] [Related]
26. Oritavancin for skin infections.
Anderson DL
Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268
[TBL] [Abstract][Full Text] [Related]
27. Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
Van Bambeke F
Ann Med; 2014 Nov; 46(7):512-29. PubMed ID: 25058176
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.
Dunbar LM; Milata J; McClure T; Wasilewski MM;
Antimicrob Agents Chemother; 2011 Jul; 55(7):3476-84. PubMed ID: 21537018
[TBL] [Abstract][Full Text] [Related]
29. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
30. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
[TBL] [Abstract][Full Text] [Related]
31. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
32. Oritavancin microbiologic features and activity results from the surveillance program in the United States.
Mendes RE; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Apr; 54 Suppl 3():S203-13. PubMed ID: 22431850
[TBL] [Abstract][Full Text] [Related]
33. Review of oritavancin for the treatment of acute bacterial skin and skin structure infections.
García Robles AA; López Briz E; Fraga Fuentes MD; Asensi Diez R; Sierra Sánchez JF
Farm Hosp; 2018 Mar; 42(2):73-81. PubMed ID: 29501059
[TBL] [Abstract][Full Text] [Related]
34. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
Van Bambeke F
Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
[TBL] [Abstract][Full Text] [Related]
35. Oritavancin--an investigational glycopeptide antibiotic.
Ward KE; Mersfelder TL; LaPlante KL
Expert Opin Investig Drugs; 2006 Apr; 15(4):417-29. PubMed ID: 16548791
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
[TBL] [Abstract][Full Text] [Related]
37. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.
Jensen IS; Wu E; Fan W; Lodise TP; Nicolau DP; Dufour S; Cyr PL; Sulham KA
J Manag Care Spec Pharm; 2016 Jun; 22(6):752-64. PubMed ID: 27231802
[TBL] [Abstract][Full Text] [Related]
38. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
[TBL] [Abstract][Full Text] [Related]
39. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
[TBL] [Abstract][Full Text] [Related]
40. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
Van Bambeke F
Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
